CS Medica Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
CS Medica's earnings have been declining at an average annual rate of -67.1%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 47.2% per year.
Key information
-67.1%
Earnings growth rate
-26.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | 47.2% |
| Return on equity | -139.4% |
| Net Margin | -1,359.8% |
| Next Earnings Update | 17 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How CS Medica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -15 | 17 | 0 |
| 30 Jun 23 | 10 | -11 | 16 | 0 |
| 31 Mar 23 | 11 | -11 | 17 | 0 |
| 31 Dec 22 | 11 | -12 | 18 | 0 |
| 30 Sep 22 | 11 | -11 | 17 | 0 |
| 30 Jun 22 | 4 | -10 | 14 | 0 |
| 31 Mar 22 | 3 | -5 | 9 | 0 |
| 31 Dec 21 | 3 | -2 | 5 | 0 |
| 30 Sep 21 | 3 | 1 | 2 | 0 |
| 30 Jun 21 | 1 | 0 | 2 | 0 |
| 30 Sep 20 | 2 | 0 | 1 | 0 |
| 30 Sep 19 | 1 | 0 | 0 | 0 |
Quality Earnings: CSMED is currently unprofitable.
Growing Profit Margin: CSMED is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CSMED is unprofitable, and losses have increased over the past 5 years at a rate of 67.1% per year.
Accelerating Growth: Unable to compare CSMED's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CSMED is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: CSMED has a negative Return on Equity (-139.36%), as it is currently unprofitable.